Diagnósticos da América (DASA3) Q2 2024 earnings summary

Executive summary

• Achieved 10% gross revenue growth and 27% EBITDA increase year-over-year in Q2 2024, with significant leverage reduction and operational improvements driven by disciplined expense management and operational excellence.

• Received a BRL 1.5 billion capital contribution (AFAC), strengthening the balance sheet, reducing net debt, and improving liquidity.

• Announced a major joint venture with Amil to create Brazil's largest independent hospital network, expected to enhance scale and profitability.

• Advanced ESG initiatives, including new leadership in internal controls, a statutory Audit Committee, and continued inclusion in B3's Corporate Sustainability Index.

Financial highlights

• Consolidated gross revenue reached BRL 4.3 billion, up 10% year-over-year; adjusted gross profit rose 12% to BRL 1.2 billion, with a 30.0% adjusted margin.

• EBITDA increased 27% year-over-year to BRL 668 million, with margin expanding by 2.4 percentage points to 16.9%.

• Net loss narrowed to -BRL 100 million, a 65% improvement year-over-year, approaching break-even.

• Investments reduced by 47% year-over-year to BRL 85 million in Q2, reflecting a focus on high-return projects.

• Cash balance of BRL 3.0 billion, covering all debt maturities for 2024 and 2025 and 1.7x debts due by end-2025.

Outlook and guidance

• Management expects continued margin improvement, operational efficiency gains, and further leverage reduction, supported by the Amil joint venture and asset optimization.

• Investment budget for 2024 set at BRL 565 million, down 22% from 2023, with most projects already approved.